Doctor Warns of 'Miserable' Constipation from Wegovy as NHS Expands to 1.2M
In a significant update for weight management in the UK, the NHS has lowered eligibility criteria for Wegovy, making free weekly injections available to approximately 1.2 million overweight individuals at risk of serious conditions like strokes and heart attacks. This GLP-1 medication, similar to Ozempic and Mounjaro, is administered as a weekly injection with dosage gradually increased as the body adjusts. However, as uptake surges, NHS doctor Suraj Kukadia has issued a stark warning about one of the most common side effects: constipation, which he describes as 'absolutely miserable' and capable of disrupting daily life.
NHS Expands Wegovy Access: Who Qualifies Now?
Weight loss jabs like Wegovy have gained massive popularity over recent years, with millions more expected to start treatment. Previously restricted to those with higher BMI levels, the NHS has broadened criteria to include adults who are overweight (BMI 27-30 kg/m² with weight-related conditions) and deemed at high risk for cardiovascular events such as heart attacks and strokes. This change aims to prevent these conditions proactively through substantial weight loss—clinical trials show Wegovy users can lose up to 15-20% of body weight over 68 weeks.
Eligibility focuses on those with comorbidities like hypertension, high cholesterol, or prediabetes, aligning with NICE guidelines. Patients must commit to lifestyle changes alongside the medication, as Wegovy (semaglutide 2.4mg weekly max dose) works best in combination with diet and exercise.
What Are GLP-1 Medications Like Wegovy?
Wegovy belongs to the GLP-1 receptor agonist class, mimicking the glucagon-like peptide-1 hormone that regulates blood sugar and appetite. Like Ozempic (semaglutide for diabetes) and Mounjaro (tirzepatide, a dual GLP-1/GIP agonist), it is injected once weekly. Starting at 0.25mg, the dose ramps up every four weeks to minimize side effects, reaching maintenance levels of 1.7mg or 2.4mg.
These drugs excel in metabolic health by promoting satiety, slowing digestion, and improving insulin sensitivity, making them transformative for obesity and type 2 diabetes management. However, their gastrointestinal effects underpin both efficacy and side effects.
Dr. Suraj Kukadia's TikTok Warning on Constipation
In a viral TikTok video viewed by his 300,000 followers, NHS doctor Suraj Kukadia (known as Dr Sooj) addressed users experiencing constipation from weight loss jabs. 'Are you on a weight loss jab, and are you really constipated?' he asked, emphasizing: 'GLP-1 medications like Ozempic, Mounjaro, Wegovy are incredibly effective for weight loss and diabetes management. But one of the most common side effects is constipation, and it can be absolutely miserable.'
"That being said, some people do get it worse than others, with higher doses tending to cause more constipation. But if you are already prone to constipation, or you're on other medications that slow down your gut, like opioids, it can be really severe." — Dr. Suraj Kukadia
Why Constipation Occurs: The Mechanism Explained
Dr. Kukadia detailed the digestive process disrupted by GLP-1s. These medications slow gastric emptying—the rate at which food moves from the stomach to the intestines. This mechanism drives weight loss: food lingers in the stomach, promoting fullness, reducing appetite, and lowering calorie intake.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
But effects extend beyond the stomach to the entire gastrointestinal tract. Intestinal contractions (peristalsis) slow, causing stool to transit more gradually. This allows excess water absorption from the stool, resulting in hard, infrequent bowel movements—classic constipation.
- Gastric emptying delay: Enhances satiety but backs up digestion.
- Reduced gut motility: Slows overall transit time (normally 24-72 hours).
- Water reabsorption: Leads to drier, harder stools.
Individual variation is key: severity depends on dose (higher = worse), baseline gut health, hydration, fiber intake, and concurrent meds like opioids or anticholinergics.
Managing Constipation from Wegovy and Other GLP-1s
While constipation affects 10-20% of users (per SELECT trial data for semaglutide), it's manageable. Dr. Kukadia's video sparks important discussions on preparation.
Practical Tips for Patients
- Increase fiber gradually: Aim for 25-30g daily from fruits, veggies, whole grains—avoid sudden jumps to prevent bloating.
- Stay hydrated: 2-3 liters of water daily softens stool.
- Exercise regularly: Walking 30 minutes post-meal stimulates motility.
- Over-the-counter aids: Bulk-forming laxatives (psyllium), stool softeners (docusate), or osmotic laxatives (polyethylene glycol) as first-line; consult your GP before use.
- Dose titration: Slower increases if issues arise.
For tracking symptoms like constipation alongside weight loss and side effects, apps like Shotlee can help log bowel habits, diet, and hydration to share with doctors.
Comparisons: Wegovy vs. Ozempic and Mounjaro Side Effects
All GLP-1s share GI risks, but profiles differ slightly:
| Drug | Active Ingredient | Constipation Rate |
|---|---|---|
| Wegovy | Semaglutide 2.4mg | ~12-24% |
| Ozempic | Semaglutide 1-2mg | ~5-20% |
| Mounjaro | Tirzepatide | ~10-20% |
Safety Considerations and When to Seek Help
Most tolerate Wegovy well long-term, but monitor for severe symptoms: abdominal pain, vomiting, or no bowel movement for >3 days signals ileus risk. Those with gastroparesis history should avoid GLP-1s. Discuss with your doctor if prone to constipation or on gut-slowing meds.
Key Takeaways: What This Means for Patients
- NHS Wegovy now for 1.2M overweight at-risk adults—great for preventing heart attacks/strokes.
- Constipation is common due to slowed gastric emptying and gut motility.
- Manage proactively with fiber, water, movement; higher doses worsen it.
- Consult GP before starting, especially if predisposed.
Conclusion
The NHS's Wegovy expansion offers hope for metabolic health, but Dr. Kukadia's warning underscores preparation for constipation. By understanding the mechanism and adopting strategies, patients can maximize benefits while minimizing 'miserable' disruptions. Speak to your healthcare provider to assess suitability and track progress effectively.
